Etilevodopa. Antiparkinsonian, dopamine precursor

Drugs of the Future

Volumn 26, Issue 3, 2001, Pages 219-223

  Sorbera, L A ^a   Martin L ^a   Leeson, P A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

2(S) Amino 3 (3,4 dihydroxyphenyl)propionic acid ethyl ester

Indexed keywords

10 (N METHYL N PROPARGYLAMINOMETHYL)DIBENZO[B,F]OXEPIN; 3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; 7 (4 METHYL 1 PIPERAZINYL) 2(3H) BENZOXAZOLONE; ADROGOLIDE; AMINO 3 (3,4 DIHYDROXYPHENYL)PROPIONIC ACID ETHYL ESTER; ANTIPARKINSON AGENT; APOMORPHINE; BIFEPRUNOX; BRASOFENSINE; BTS 74398; CARBIDOPA; ETILEVODOPA; GMC 1111; LEVODOPA METHYL ESTER; O 1369; PNU 95666A; ROTIGOTINE; S 32504; SPD 451; UNCLASSIFIED DRUG; ZYDIS APOMORPHINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; ERYTHEMA; HUMAN; NONHUMAN; PARKINSONISM; RAT; VERTIGO;

EID: 0034981540     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.03.615455     Document Type: Article

References (18)

1. Facile synthesis of L-dopa esters by the combined use of tyrosinase and α-chymotrypsin
2. Management of Parkinson's disease: A review of current and new therapies
3. L-DOPA esters as potential prodrugs. Part I. Physicochemical properties
4. L-DOPA esters as potential prodrugs. Part II. Chemical and enzymatic hydrolysis
5. L-Dopa esters as potential prodrugs: Behavioural activity in experimental models of Parkinson's disease
6. L-Dopa esters as potential prodrugs: Effect on brain concentration of dopamine metabolites in reserpinized mice
7. Esters of L-dopa: Structure-hydrolysis relationships and ability to induce circling behaviour in an experimental model of hemiparkinsonism
8. Intestinal hydrolysis of TV-1203, a levodopa prodrug
9. Effect of subcutaneous administration of levodopa ethyl ester, a soluble prodrug of levodopa, on dopamine metabolism in rodent striatum: Implication for treatment of Parkinson's disease
10. Levodopa ethylester: A novel rescue therapy for response fluctuations in Parkinson's disease
11. Subcutaneous injections of levodopa ethylester: A potential novel rescue therapy for response fluctuations in patients with Parkinson's disease
12. Levodopa ethylester: A novel therapeutic strategy for treatment of response fluctuations in patients with Parkinson's disease
13. Double-blind, crossover trial of oral levodopa ethylester vs. crushed levodopa for treatment of response fluctuations in Parkinson's disease
14. Teva finalizes separate agreements with Aventis and Lundbeck
15. Important advances in the Lundbeck pipeline during 2000